Trial reportEye (London, England)2019
Oral fluoxetine in the management of amblyopic patients aged between 10 and 40 years old: a randomized clinical trial.
Trial report in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07226141 (Valproate for the Treatment of Residual Amblyopia), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Valproate for the Treatment of Residual Amblyopia
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Research hotspots and trends of amblyopia treatment from 2015 to 2025: a bibliometric analysis.Frontiers in neuroscience · 2025Pooled it
- Selective serotonin reuptake inhibitors for amblyopia treatment: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurologyPooled it
- Treatment strategies for amblyopia in adults: an overview of conventional methods and new technologies.Romanian journal of ophthalmologyPooled it
- Durable recovery from amblyopia with donepezil.Scientific reports · 2023Trial
- The Effect of Combined Patching and Citalopram on Visual Acuity in Adults with Amblyopia: A Randomized, Crossover, Placebo-Controlled Trial.Neural plasticity · 2019Trial
- Systematic Review and Meta-Analysis of RCTs on Efficacy of Conventional vs. Emerging Treatments for Amblyopia.Life (Basel, Switzerland) · 2026Review
- Child Maltreatment and Psychopathology: A Brief Review on the Potential Role of the Hypothalamic-pituitary-adrenal Axis.Current pediatric reviews · 2025Review
- Understanding amblyopia from the perspective of neurovascular units: changes in the retina and brain.Frontiers in cell and developmental biology · 2025Review
- Evaluation of the clinical effect of 4D digital strabismus and amblyopia visual function correction system combined with traditional comprehensive treatment methods on anisometropic amblyopia.BMC ophthalmology · 2024Article
- The relationship between visual acuity loss and GABAergic inhibition in amblyopia.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Comprehensive review of amblyopia: Types and management.Indian journal of ophthalmology · 2023Review
- Human deprivation amblyopia: treatment insights from animal models.Frontiers in neuroscience · 2023Article
- Metaplasticity: a key to visual recovery from amblyopia in adulthood?Current opinion in ophthalmology · 2022Review
- Childhood Trauma, the HPA Axis and Psychiatric Illnesses: A Targeted Literature Synthesis.Frontiers in psychiatry · 2022Review
- An update on pharmacological treatment options for amblyopia.International ophthalmology · 2020Review
- Cortical Tuning is Impaired After Perceptual Experience in Primary Visual Cortex of Serotonin Transporter-Deficient Mice.Cerebral cortex communications · 2020Article
- Characterization, passive and active treatment in strabismic amblyopia: a narrative review.International journal of ophthalmology · 2020Review
- Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to assess the efficacy of oral fluoxetine therapy in improving the visual function of amblyopic patients aged between 10 and 40 years old.
methodsIn this double-blinded, randomized, controlled trial (IRCT2016052428046N1; registered retrospectively), 40 eligible participants with anisometropic or mixed amblyopia were randomly assigned to either fluoxetine or placebo groups. Participants with anisometropia and logMAR best spectacle-corrected visual acuity (BSCVA) worse than 0.2 logMAR in the amblyopic eye or at least a two-line of difference in the BSCVA between the fellow eyes were included. Participants with significant ocular or systemic diseases were excluded. In both groups, the better eye of each patient was patched for 4-6 h a day during the study period. Participants in the treatment group were treated with oral fluoxetine for 3 months. Change in the Snellen BSCVA (after 3 months) was regarded as the primary outcome measure.
resultsData from 20 participants in the fluoxetine group and 15 participants from the placebo group were analyzed (aged 11-37 years). The magnitude of improvement in visual acuity (from baseline to 3 months after treatment) was significantly higher in the fluoxetine group (0.240 ± 0.068 logMAR; 2.4 line-gain) compared with the control group (0.120 ± 0.086 logMAR; 1.2 line-gain).
conclusionsThis study suggests beneficial effects of fluoxetine in the management of adult and adolescent amblyopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.